Integrated Filing — IndAS

General information about company
Scrip Code	530019
NSE Symbol	JUBLPHARMA
MSEI Symbol	NOTLISTED
ISIN	INE700A01033
Name of company	JUBILANT PHARMOVA LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	16-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	30-Apr-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Multi segment
Description of single segment
Start date and time of board meeting	16-May-2025   10:30:00
End date and time of board meeting	16-May-2025   13:15:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	19288000000	72345000000
	Other income	119000000	568000000
	Total income	19407000000	72913000000
2	Expenses
(a)	Cost of materials consumed	5840000000	19853000000
(b)	Purchases of stock-in-trade	848000000	2971000000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-427000000	346000000
(d)	Employee benefit expense	5906000000	22679000000
(e)	Finance costs	527000000	2403000000
(f)	Depreciation, depletion and amortisation expense	952000000	3686000000
(f)	Other Expenses
1	Other Expenses	3667000000	14759000000
	Total other expenses	3667000000	14759000000
	Total expenses	17313000000	66697000000
3	Total profit before exceptional items and tax	2094000000	6216000000
4	Exceptional items	-33000000	3595000000
5	Total profit before tax	2061000000	9811000000
6	Tax expense
7	Current tax	1148000000	2132000000
8	Deferred tax	-601000000	-689000000
9	Total tax expenses	547000000	1443000000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	1514000000	8368000000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	-1000000	-5000000
16	Total profit (loss) for period	1513000000	8363000000
17	Other comprehensive income net of taxes	-46000000	850000000
18	Total Comprehensive Income for the period	1467000000	9213000000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	1536000000	8394000000
	Total profit or loss, attributable to non-controlling interests	-23000000	-23000000
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	1489000000	9247000000
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	-22000000	-34000000
21	Details of equity share capital
	Paid-up equity share capital	158000000	158000000
	Face value of equity share capital	1	1
27	Details of debt securities
22	Reserves excluding revaluation reserve		62391000000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	9.71	52.99
	Diluted earnings (loss) per share from continuing operations	9.68	52.85
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	9.71	52.99
	Diluted earnings (loss) per share from continuing and discontinued operations	9.68	52.85
24	Debt equity ratio
25	Debt service coverage ratio
26	Interest service coverage ratio
27	Disclosure of notes on financial results

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Consolidated
	Assets
1	Non-current assets
	Property, plant and equipment	21323000000
	Capital work-in-progress	27147000000
	Investment property	0
	Goodwill	25410000000
	Other intangible assets	1814000000
	Intangible assets under development	9153000000
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	75000000
	Non-current financial assets
	Non-current investments	360000000
	Trade receivables, non-current	0
	Loans, non-current	3000000
	Other non-current financial assets	266000000
	Total non-current financial assets	629000000
	Deferred tax assets (net)	2574000000
	Other non-current assets	3667000000
	Total non-current assets	91792000000
2	Current assets
	Inventories	11292000000
	Current financial asset
	Current investments	0
	Trade receivables, current	8915000000
	Cash and cash equivalents	10883000000
	Bank balance other than cash and cash equivalents	5000000
	Loans, current	11000000
	Other current financial assets	1605000000
	Total current financial assets	21419000000
	Current tax assets (net)	180000000
	Other current assets	2206000000
	Total current assets	35097000000
3	Non-current assets classified as held for sale	675000000
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	127564000000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	158000000
	Other equity	62391000000
	Total equity attributable to owners of parent	62549000000
	Non controlling interest	-163000000
	Total equity	62386000000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	21503000000
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
	Total Trade payable
	Other non-current financial liabilities	7741000000
	Total non-current financial liabilities	29244000000
	Provisions, non-current	1191000000
	Deferred tax liabilities (net)	1722000000
	Deferred government grants, Non-current	0
	Other non-current liabilities	11375000000
	Total non-current liabilities	43532000000
	Current liabilities
	Current financial liabilities
	Borrowings, current	2866000000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	343000000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	9705000000
	Total Trade payable	10048000000
	Other current financial liabilities	5743000000
	Total current financial liabilities	18657000000
	Other current liabilities	2021000000
	Provisions, current	784000000
	Current tax liabilities (Net)	184000000
	Deferred government grants, Current	0
	Total current liabilities	21646000000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	65178000000
	Total equity and liabilites	127564000000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
1	Radiopharma	8951000000	33880000000
2	Allergy Immunotherapy	1919000000	7142000000
3	Contract Development and Manufacturing Organisation - Sterile Injectables	3723000000	13527000000
4	Contract Research, Development and Manufacturing Organisation	3435000000	11728000000
5	Generics	1573000000	6853000000
6	Proprietary Novel Drugs	0	0
7	Unallocable corporate	68000000	372000000
	Total Segment Revenue	19669000000	73502000000
	Less: Inter segment revenue	381000000	381000000
	Revenue from operations	19288000000	72345000000
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
1	Radiopharma	1042000000	3955000000
2	Allergy Immunotherapy	867000000	2403000000
3	Contract Development and Manufacturing Organisation - Sterile Injectables	761000000	2179000000
4	Contract Research, Development and Manufacturing Organisation	549000000	1276000000
5	Generics	-293000000	-232000000
6	Proprietary Novel Drugs	-36000000	-183000000
7	Unallocable corporate	0	0
	Total Profit before tax	2890000000	9398000000
	i. Finance cost	527000000	527000000
	ii. Other Unallocable Expenditure net off Unallocable income	303000000	303000000
	Profit before tax	2060000000	9806000000
3	(Segment Asset - Segment Liabilities)
	Segment Asset
1	Radiopharma	28803000000	28803000000
2	Allergy Immunotherapy	7979000000	7979000000
3	Contract Development and Manufacturing Organisation - Sterile Injectables	43481000000	43481000000
4	Contract Research, Development and Manufacturing Organisation	17460000000	17460000000
5	Generics	11622000000	11622000000
6	Proprietary Novel Drugs	2699000000	2699000000
7	Unallocable corporate	15520000000	15520000000
	Total Segment Asset	127564000000	127564000000
	Un-allocable Assets	0	0
	Net Segment Asset	127564000000	127564000000
4	Segment Liabilities
	Segment Liabilities
1	Radiopharma	9177000000	9177000000
2	Allergy Immunotherapy	958000000	958000000
3	Contract Development and Manufacturing Organisation - Sterile Injectables	21524000000	21524000000
4	Contract Research, Development and Manufacturing Organisation	3961000000	3961000000
5	Generics	2404000000	2404000000
6	Proprietary Novel Drugs	89000000	89000000
7	Unallocable corporate	27065000000	27065000000
	Total Segment Liabilities	65178000000	65178000000
	Un-allocable Liabilities	0	0
	Net Segment Liabilities	65178000000	65178000000
	Disclosure of notes on segments

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
1	Items that will not be reclassified to profit or loss	8000000	-3000000
	Total Amount of items that will not be reclassified to profit and loss	8000000	-3000000
2	Income tax relating to items that will not be reclassified to profit or loss	-4000000	-8000000
3	Amount of items that will be reclassified to profit and loss
1	Items that will be reclassified to profit or loss	-58000000	845000000
	Total Amount of items that will be reclassified to profit and loss	-58000000	845000000
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	-46000000	850000000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Consolidated
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			9811000000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			2403000000
	Adjustments for decrease (increase) in inventories			785000000
	Adjustments for decrease (increase) in trade receivables, current			242000000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-292000000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			0
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			553000000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			-170000000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			3686000000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			0
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			0
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			1000000
	Adjustments for dividend income			0
	Adjustments for interest income			366000000
	Adjustments for share-based payments			43000000
	Adjustments for fair value losses (gains)			17000000
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			0
	Other adjustments to reconcile profit (loss)			0
	Other adjustments for non-cash items			-3608000000
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			3294000000
	Net cash flows from (used in) operations			13105000000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			2384000000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			10721000000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			9521000000
	Other cash payments to acquire equity or debt instruments of other entities			14000000
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			50000000
	Purchase of property, plant and equipment			11156000000
	Proceeds from sales of investment property			0
	Purchase of investment property			0
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			6095000000
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			384000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			-3000000
	Net cash flows from (used in) investing activities	4877000000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			56000000
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			9000000
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			274000000
	Repayments of borrowings			11004000000
	Payments of lease liabilities			598000000
	Dividends paid			796000000
	Interest paid			2356000000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) financing activities			-14527000000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			1071000000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			248000000
	Net increase (decrease) in cash and cash equivalents			1319000000
	Cash and cash equivalents cash flow statement at beginning of period			9564000000
	Cash and cash equivalents cash flow statement at end of period			10883000000